Overview

T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)

Status:
Terminated
Trial end date:
2011-07-15
Target enrollment:
Participant gender:
Summary
Clofarabine is a drug approved by the FDA (Food and Drug Administration) for treating children (age 1-21) with leukemia. This research study will use clofarabine with two other cancer fighting drugs. Clofarabine will be used together with etoposide (VePesid®, VP-16) and cyclophosphamide (Cytoxan®).
Phase:
Phase 2
Details
Lead Sponsor:
Therapeutic Advances in Childhood Leukemia Consortium
Collaborator:
Genzyme, a Sanofi Company
Treatments:
Clofarabine
Cyclophosphamide
Cytarabine
Etoposide
Etoposide phosphate
Lenograstim
Sargramostim